PORT HUENEME, CA--(Marketwire - September 30, 2010) - (
Stellar's customer also announced the RA market for its therapy in 7 major markets is 200,000 patients, and gained consent to proceed to a higher dose in Phase I/II study of their Stellar KLH-based IFN-alpha kinoid in lupus patients.
Neovacs SA http://www.neovacs.fr/ is a biotechnology company focused on an active immunotherapy technology platform, holds a broad patent portfolio and is developing therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
Stellar Biotechnologies, Inc. (
There are forward-looking statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
Contact:
Darrell Brookstein
Executive VP
DBrookstein@StellarBiotech.com
Stellar's press releases: http://www.stellarbiotechnologies.com/investors/news_releases/
Corporate Profile: http://www.stellarbiotechnologies.com/investors/presentation/